4SC AG — Share Issue/Capital Change 2011

Feb 24, 2011

News Details

Ad-hoc | 24 February 2011 15:20

4SC Completes Capital Increase

4SC AG / Key word(s): Capital Increase

24.02.2011 15:20

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Planegg-Martinsried, Germany, 24 February, 2011 -4SC AG (Frankfurt, Prime
Standard: VSC), a drug discovery and development company focused on
autoimmune and cancer indications, has today raised gross proceeds of
approximately EUR 11.74 million and placed 3,452,647 new shares with
institutional investors at a price of EUR 3.40 per share. The subscription
rights of the existing shareholders were excluded.

The Company's number of issued no-par value bearer shares thereby increases
from 38,502,739 shares to 41,955,386 shares. The completion of the capital
increase is expected to be registered with the Commercial Register on 25
February, 2011. The admission of the new shares to trading on the Regulated
Market of the Frankfurt Stock Exchange (Prime Standard) is expected to
occur on 28, February 2011.

Kempen & Co. acted as Lead Manager, Donner & Reuschel Privatbank as Listing
Agent and Trout Capital LLC as Advisor to the transaction.

• End of Ad-hoc Announcement

About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in Phase IIb development in rheumatoid
arthritis and inflammatory bowel disease (IBD), for which positive results
from a Phase IIa study were recently reported. The company's lead oncology
compound, resminostat (4SC-201), an oral pan-histone deacetylase (HDAC)
inhibitor, is in Phase II trials in hepatocellular carcinoma, Hodgkin's
lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds,
4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates
until proof-of-concept in order to generate value creating partnerships
with the pharmaceutical industry in return for advance and milestone
payments as well as royalties.

Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.

For further information, please visit www.4sc.com.

Disclaimer

This publication may contain projections or estimates relating to plans and
objectives relating to future operations, products, or services, future
financial results or assumptions underlying or relating to any such
statements. These forward looking statements are subject
to risks and uncertainties, which cannot be foreseen and which are beyond
the control of 4SC AG. Many factors can cause actual results to differ
materially from any estimates expressed or implied by this publication. 4SC
AG has no obligation to periodically update or release any
revisions to the forward-looking statements contained in this publication
to reflect events or circumstances after the date of this release.

This publication constitutes neither an offer to sell nor a solicitation to
buy securities of 4SC AG. The shares of 4SC AG may only be
offered or sold in the United States after registration or without
registration under an exemption from the registration requirements of the
U.S. Securities Act of 1933, as 4SC AG has no obligation to periodically
update or release any revisions to the forward-looking statements contained
in this release to reflect events or circumstances after the date of this
release. Shares have not been and will not be registered under the
Securities Act. 4SC AG intends no public offering of the shares in the
United States.

For more information please contact:

4SC AG
Yvonne Alexander, IR & PR
Tel.: +49 (0) 89 70 07 63 66

MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 30

The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947

24.02.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---